Pharma

Your Article Summary

See Latest Articles

Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
Chugai Pharmaceutical Co., 08/17/09

Chugai Pharmaceutical Co., Ltd. announced that Phase III study of the recombinant human erythropoietin "Epogin Injection" achieved the primary endpoint by significantly reducing the theoretical transfusion rate* in patients with chemotherapy induced anemia.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09

Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09

 See all of Drug Trials